Heart-valve manufacturer Edwards Lifesciences ( EW) said its second-quarter earnings jumped, helped by strong operating performance and sales growth from critical care and vascular products. The Irvine, Calif.-based company earned $36.1 million, or 58 cents a share, in the quarter, compared with $13.9 million, or 22 cents a share, a year ago. Adjusted for items, earnings were 59 cents a share in the most recent quarter. Analysts polled by Thomson First Call were expecting earnings of 50 cents a share in the most recent quarter. Second-quarter revenue rose 3.5% to $267.3 million, though hurt by foreign exchange and sales from discontinued businesses, as against analysts' expectation of $266.45 million. The company expects to earn 45 cents to 47 cents a share in the third quarter, including 5 cents a share of options expenses. For the full year, the company raised its guidance earnings of $2.21 a share to $2.27 a share, excluding special items and 21 cents a share of options expenses, on revenue of $1.04 billion to $1.06 billion. Analysts are expecting earnings of 47 cents a share for the third quarter and $2.0 a share for the full year on revenue of $1.052 billion. Gross profit rose 7% to $171.6 million while gross profit margin rose 210 basis points to 64.2% owing to a favorable foreign exchange impact and last year's divestiture of the low margin perfusion product line in Japan. Sales in heart valve therapy increased 1.7% to $127.8 million and in critical care segment they increased 9.8% to $89.6 million. Cardiac surgery systems sales decreased 7.3% to $24.3 million and vascular's sales increased 13% to $19.1 million. The company acquired about 1.3 million shares of its common stock for $56 million. "During the quarter, we made good progress on all of our strategic growth initiatives, most notably in our percutaneous and Ascendra heart valve programs." the company said.